Recruiting

PsA DiagnosisModifying PEST for Psoriatic Arthritis Screening

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06382051

Conditions

Plaque Psoriasis

Psoriatic Arthritis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

PEST Screening group

Study Details

Brief summary:

The purpose of this study is to assess the impact of adding two questions and pictures to the validated PEST on the potential diagnosis of PsA in participants with moderate-to-severe plaque PsO in Canada.

Conditions

Plaque Psoriasis

Psoriatic Arthritis

Study ID

NCT06382051

Start date

Jan 23, 2025

Status verified date

Aug, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Key inclusion criteria:

1. Moderate-to-severe plaque PsO patients who are candidates for bDMARDs, according to physician's clinical judgement at the time of patient enrollment.
2. Adult patients at the time of informed consent signature
3. Patients able to understand and willing to comply with protocol requirements, instructions, and restrictions
4. Residents of Canada

Key exclusion criteria:

1. Patients who have previously screened positive for PsA through PEST.
2. Patients who have been diagnosed with PsA.
3. Patients who have been diagnosed with inflammatory arthritis unrelated to PsA (rheumatoid arthritis, reactive arthritis, enteropathic arthritis, axial spondyloarthritis)
4. Patients treated with a bDMARD for moderate-to-severe plaque PsO or any other medical condition within the last 6 months prior to patient enrollment.

Study Design

Enrollment

502 participants

Anticipated

Intervention Model

Single group

Primary purpose

Screening

Interventions and Outcome Measures

Arms

other: PEST Screening group

When visiting their dermatologists, all eligible patients with moderate-to-severe plaque psoriasis (PsO) eligible for treatment with biologic Disease-Modifying Antirheumatic Drugs (bDMARDs) will be screened for psoriatic arthritis (PsA) using PEST+pictures+2, a variation of the PEST screening tool.

The PEST+pictures+2 is made up of 3 components:

1. Psoriasis Epidemiology Screening Tool (PEST) consisting of 5 simple questions
2. PEST+2 refers to the PEST modified with two additional questions (Do you have morning stiffness that lasts for more than one (1) hour? Do you wake up at night because of low back or buttock pain?), AND
3. PEST+pictures which provides an opportunity for patients to modify their answers to PEST questions 1, 3, and 5 by presenting them with pictures of swollen joints, fingernail pitting, and swollen fingers and toes.

Interventions

PEST Screening group

Primary outcome measure

Positive Predictive Value (PPV) for PEST and PEST+2 in adult patients with moderate-to-severe plaque PsO who are candidates for bDMARDs [ Time Frame: Up to approximately 1 year ]

Central Contacts and Locations

Central contacts

Novartis Pharmaceuticals

+41613241111 novartis.email@novartis.com

Novartis Pharmaceuticals

novartis.email@novartis.com

Locations

Novartis Investigative Site

Recruiting

Calgary, Alberta, Canada, T2J 7E1

Novartis Investigative Site

Recruiting

Edmonton, Alberta, Canada, T5J 3S9

Novartis Investigative Site

Recruiting

Edmonton, Alberta, Canada, T6G 2C8

Novartis Investigative Site

Recruiting

Kelowna, British Columbia, Canada, V1W 4V5

Novartis Investigative Site

Recruiting

Surrey, British Columbia, Canada, V3R 6A7

Novartis Investigative Site

Recruiting

Winnipeg, Manitoba, Canada, R3C 0N2

Novartis Investigative Site

Recruiting

Fredericton, New Brunswick, Canada, E3B 1G9

Novartis Investigative Site

Recruiting

Barrie, Ontario, Canada, L4M 6L2

Novartis Investigative Site

Recruiting

Greater Sudbury, Ontario, Canada, P3C 1X8

Novartis Investigative Site

Recruiting

Hamilton, Ontario, Canada, L8J 0G5

Novartis Investigative Site

Recruiting

Hamilton, Ontario, Canada, L8N 1V6

Novartis Investigative Site

Recruiting

Hamilton, Ontario, Canada, L8P4B4

Novartis Investigative Site

Recruiting

London, Ontario, Canada, N6A 5R9

Novartis Investigative Site

Recruiting

London, Ontario, Canada, N6G 0W7

Novartis Investigative Site

Recruiting

Markham, Ontario, Canada, L3R 2C7

Novartis Investigative Site

Recruiting

Ottawa, Ontario, Canada, K2A 3Z3

Novartis Investigative Site

Recruiting

Richmond Hill, Ontario, Canada, L4C 9M7

Novartis Investigative Site

Recruiting

Stoney Creek, Ontario, Canada, L8G 1H1

Novartis Investigative Site

Recruiting

Toronto, Ontario, Canada, M4A2S8

Novartis Investigative Site

Recruiting

Toronto, Ontario, Canada, M5S 1B6

Novartis Investigative Site

Recruiting

Waterloo, Ontario, Canada, N2J 1C4

Novartis Investigative Site

Recruiting

Montreal, Quebec, Canada, H1T 2M4

Novartis Investigative Site

Recruiting

Montreal, Quebec, Canada, H1Y 3L1

Novartis Investigative Site

Recruiting

Montreal, Quebec, Canada, H4A 3T2

Novartis Investigative Site

Recruiting

Québec, Quebec, Canada, G1V 4X7

Novartis Investigative Site

Recruiting

Québec, Quebec, Canada, G1W 4R4

Novartis Investigative Site

Recruiting

Ste-Foy, Quebec, Canada, G1V 4G2

Novartis Investigative Site

Recruiting

Verdun, Quebec, Canada, H4G 3E7

Novartis Investigative Site

Recruiting

Saskatoon, Saskatchewan, Canada, S7K 2C1

Novartis Investigative Site

Recruiting

Saskatoon, Saskatchewan, Canada, S7K0H6

More Information

Sponsor

Novartis Pharmaceuticals

Last update posted

Aug 21, 2026

Last verified

Aug, 2026

Keywords

Psoriasis
Psoriatic Arthritis
PsA
Plaque Psoriasis
PsO
Implementation Science
Psoriasis Epidemiology Screening Tool

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Novartis Pharmaceuticals on 2026-08-21.